Loading page…

Biogen Pharmachem Industries Ltd (BIOGEN) · mywealthgrid

About

Biogen Pharmachem Industries Ltd operates in Other Financial Services within the Financials sector.

Face value: ₹1

Market cap

₹28 Cr

P/E

—

P/B

0.2×

Dividend yield

ROE

0.9%

ROCE

Debt / equity

OPM

37.5%

EPS (TTM)

₹-0.0

Book value

₹1.1

52-week high

₹0.8

52-week low

₹0.3

₹0.3-63.4%1Y

Beta

1.09

Moves with the index

Volatility (1y)

57.4%

Annualised, daily returns

RSI (14)

Neither overbought nor oversold

Rel. strength (1y)

-72.1%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Healthy operating margin of 37.5%
+Profit CAGR of 23.2% over the last 3 years
+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of 1.3% (3-yr avg)
−Modest revenue growth of 9.6% a year over the last 5 years
−Trading 64.2% below its 52-week high

Research score

Structured signal from quality, growth, valuation and momentum.

47/100

Business quality: 50
Growth: 89
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Crisil LimitedCRISILCRISIL	₹32,373 Cr	₹32,373 Cr	₹4,126 Cr	₹1,229 Cr	29.7%	₹884 Cr	21%	33.9%	27.4%	48
RRP Semiconductor LtdRRPRRP	₹11,162 Cr	₹11,168 Cr	₹-7 Cr	₹-7 Cr	—	₹-8 Cr	—	-32.7%	-59.8%	—
Onemi Technology Solutions LimitedKISSHTKISSHT	₹6,254 Cr	₹7,346 Cr	₹2,179 Cr	₹651 Cr	29.9%	₹281 Cr	12.9%	32.9%	21%	-8
Asset Reconstruction Company (India) LimitedARCILARCIL	₹4,546 Cr	₹5,751 Cr	₹722 Cr	₹473 Cr	65.5%	₹-36 Cr	44.7%	—	-1.3%	—
Colab Platforms LtdCOLABCOLAB	₹2,622 Cr	₹2,624 Cr	₹158 Cr	₹2 Cr	1%	₹5 Cr	2.9%	23.2%	17.2%	9
Gyftr LtdGYFTRGYFTR	₹1,204 Cr	₹1,240 Cr	₹14 Cr	₹3 Cr	21.6%	₹2 Cr	12.9%	—	0.5%	—
Prime Securities LimitedPRIMESECUPRIMESECU	₹1,022 Cr	₹1,024 Cr	₹125 Cr	₹13 Cr	15.7%	₹5 Cr	9.6%	—	6.7%	—
Centrum Capital LimitedCENTRUMCENTRUM	₹969 Cr	₹17,026 Cr	₹3,643 Cr	₹948 Cr	29.2%	₹-217 Cr	-7.5%	12.7%	-46.8%	-519
Wealth First Portfolio Managers LimitedWEALTHWEALTH	₹952 Cr	₹952 Cr	₹58 Cr	₹37 Cr	72.3%	₹33 Cr	56%	34.5%	27.7%	563
Stellant Securities (India) LtdSTELLANTSTELLANT	₹518 Cr	₹518 Cr	₹0 Cr	₹-0 Cr	-93.8%	₹-0 Cr	-93.8%	-45.5%	-44.8%	0
The Investment Trust Of India LimitedTHEINVESTTHEINVEST	₹472 Cr	₹523 Cr	₹274 Cr	₹48 Cr	20.2%	₹33 Cr	12.2%	8.5%	4.2%	-42
Ndl Ventures LimitedNDLVENTURENDLVENTURE	₹422 Cr	₹1,328 Cr	₹1,044 Cr	₹149 Cr	17%	₹-38 Cr	0.2%	4.4%	-5.9%	-739

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	—	—	—	—	2	2	1	0	1	3
Interest	—	—	—	—	0	0	0	0	0	0
Expenses	0	0	1	0	2	2	0	0	1	2
Financing profit	—	—	—	—	0	-0	0	-0	-0	1
Financing margin %	—	—	—	—	0%	-0.9%	55.4%	0%	-34.5%	37.5%
Other income	—	—	—	—	-2	0	0	2	0	0
Depreciation	—	—	—	—	0	0	0	0	0	0
Profit before tax	-0	-7	0	-0	-2	-0	0	2	-0	1
Tax	—	—	—	—	0	0	0	0	0	0
Tax %	—	—	—	—	0%	0%	0%	0%	0%	10.4%
PAT	-0	-7	0	-0	-2	-0	0	2	-0	1
EPS (₹)	—	—	—	—	-0	0	0	0	0	0
EPS adjusted (₹)	—	—	—	—	-0	-0	0	0	-0	0
Annual report	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	65	65	65	65	65	90
Reserves	-11	-11	-11	-9	27	9
	0	1	0	0	0	0
	0	-0	0	0	0	0
Total equity & liabilities	54	55	55	57	92	99
	0	0	0	0	0	0
CWIP	0	0	0	0	0	0
Investments	9	7	9	5	24	33
	45	48	46	51	68	67
Total assets	54	55	55	57	92	99

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	8.6%	6.9%	—	—	—	—
EBITDA margin %	—	—	0%	-0.9%	55.4%	—	-34.5%	37.5%
EBIT margin %	—	—	0%	-0.9%	55.4%	—	-34.5%	37.5%
PAT margin %	—	—	-98.8%	-0.5%	55.4%	—	-34.5%	33.6%
Working capital
Receivable days	—	—	559	0	0	—	0	0
Inventory days	—	—	0	0	0	—	0	0
Payable days	—	—	0	0	0	—	0	0
NWC days	—	—	559	0	0	—	0	0
Leverage
Current ratio	—	—	50	2.35	0.93	0.23	29.56	2.33
Debt to EBITDA	—	—	—	—	0	—	—	0
Debt to equity	—	—	0	0.02	0	0	0	0
Interest coverage	—	—	—	—	—	—	—	—
Asset turnover	—	—	0.03	0.04	0.02	0	0.01	0.03
Return ratios
Return on assets %	—	—	-3%	-0%	0.8%	3.4%	-0.3%	0.9%
Return on capital employed %	—	—	-3%	-0%	0.8%	3.5%	-0.4%	1%
Return on equity %	—	—	-3%	-0%	0.8%	3.4%	-0.3%	0.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoter	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
No. of shareholders	—	—	—	—	—	—	—	—	2,93,327	2,89,987	2,89,155	2,93,626

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Biogen Pharmachem Industries Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results5 Aug 2026

1

Bonus 1:615 May 2026 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

47 announcementsExport CSV

14 May 2026, 4:46 pmResult

Regulation 33 Read With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Financial Results PDF

14 May 2026, 4:42 pmBoard Meeting

Board Meeting Outcome for Audited Financial Results Of The Company For The Quarter And Year Ended On 31St March, 2026 And Outcome Of The Board Meeting Held On Thursday 14Th May 2026.

Outcome of Board Meeting PDF

4 May 2026, 5:11 pmBoard Meeting

Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting.

Exchange filing PDF

27 Apr 2026, 7:30 pmCompany Update

Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association

Amendments to Memorandum & Articles of Association PDF

27 Apr 2026, 5:25 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

Postal Ballot PDF

27 Apr 2026, 5:17 pmAGM/EGM

Biogen Pharmachem Industries Ltd - 531752 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

Postal Ballot PDF

22 Apr 2026, 5:59 pmOthers

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A PDF

6 Apr 2026, 5:42 pmCompany Update

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 PDF

Date	Category	Subject	Filing
14 May 2026, 4:46 pm	Result Financial Results	Regulation 33 Read With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")	PDF
14 May 2026, 4:42 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Audited Financial Results Of The Company For The Quarter And Year Ended On 31St March, 2026 And Outcome Of The Board Meeting Held On Thursday 14Th May 2026.

Loading announcements…

68 deals · 5 Aug 2021 – 4 May 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
4 May 2026	MOHANRAMESH	Bulk	BSE	Buy	51,00,000	₹0.49	₹0.25 Cr
10 Jul 2024	TOPGAIN FINANCE PRIVATE LIMITED	Bulk	BSE	Sell	33,55,000	₹1.30	₹0.44 Cr
9 Jul 2024	TOPGAIN FINANCE PRIVATE LIMITED	Bulk	BSE	Buy	44,40,901	₹1.44	₹0.64 Cr
9 Jul 2024	TOPGAIN FINANCE PRIVATE LIMITED	Bulk	BSE	Sell	10,85,901	₹1.44	₹0.16 Cr
5 Jul 2024	JAI VINAYAK SECURITIES	Bulk	BSE	Sell	36,20,035	₹1.70	₹0.62 Cr
5 Jul 2024	JAI VINAYAK SECURITIES	Bulk	BSE	Buy	32,74,609	₹1.72	₹0.56 Cr
3 Jul 2024	TOPGAIN FINANCE PRIVATE LIMITED	Bulk	BSE	Buy	37,80,832	₹1.23	₹0.47 Cr
3 Jul 2024	TOPGAIN FINANCE PRIVATE LIMITED	Bulk	BSE	Sell	37,80,832	₹1.23	₹0.47 Cr
3 Jul 2024	SAHASTRAA ADVISORS PRIVATE LIMITED	Bulk	BSE	Buy	37,78,839	₹1.23	₹0.46 Cr
3 Jul 2024	SAHASTRAA ADVISORS PRIVATE LIMITED	Bulk	BSE	Sell	32,91,682	₹1.25	₹0.41 Cr

1–10 of 68

1 / 7

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	4	1	2	2	-1	2
	-4	-1	-2	-2	-33	-10
	-0	0	0	0	36	6
Net cash flow	0	0	0	-0	2	-2
Free cash flow	4	1	2	2	-1	2
CFO / Operating profit %	—	—	354.4%	—	—	163.5%

Biogen Pharmachem Industries Ltd

Biogen Pharmachem Industries Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

1

1

Announcements

1

1

No fund holdings on record

Announcements

Annual reports

Not in the F&O segment

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Biogen Pharmachem Industries Ltd

Biogen Pharmachem Industries Ltd

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Bonus issues1

Announcements

Board meetings1

Bonus issues1

Ratio timeline

No fund holdings on record

Announcements

Quarterly record

Annual reports

Bulk & block deals

Board and management

Not in the F&O segment

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

1

1

1

1